Showing 11 - 20 of 161,086
Although cannabis is federally prohibited, a majority U.S. states have implemented medical cannabis laws (MCLs). As more individuals consider the drug for medical treatment, they potentially substitute away from prescription drugs. Therefore, an MCL signals competitor entry. This paper exploits...
Persistent link: https://www.econbiz.de/10012826586
available and useable by all. This submission presents evidence on delays to generic entry in Australia then considers (briefly …
Persistent link: https://www.econbiz.de/10014149017
proliferate, the costs of pharmaceuticals take increasingly larger shares of most countries' health service spending, and … alliance to combine their respective pharmaceutical regulatory agencies, Australia's Therapeutic Goods Administration (TGA) and …
Persistent link: https://www.econbiz.de/10014055619
Persistent link: https://www.econbiz.de/10011618088
Persistent link: https://www.econbiz.de/10002481759
Persistent link: https://www.econbiz.de/10009741232
This paper compares the clinical trial strategies and performance of large, established ("mature") biopharmaceutical firms to those of smaller ("early stage") firms that have not yet successfully developed a drug. We study a sample of 235 cancer drug candidates that entered clinical trials...
Persistent link: https://www.econbiz.de/10012467754
Persistent link: https://www.econbiz.de/10013342769
Persistent link: https://www.econbiz.de/10013343552
This paper compares the clinical trial strategies and performance of large, established (quot;maturequot;) biopharmaceutical firms to those of smaller (quot;early stagequot;) firms that have not yet successfully developed a drug. We study a sample of 235 cancer drug candidates that entered...
Persistent link: https://www.econbiz.de/10012752635